184 related articles for article (PubMed ID: 33282092)
1. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
July J; Patricia D; Gunawan PY; Setiajaya H; Ginting TE; Putra TP; Wuisan Z; Budhiarko D; Masykura N; Prayogi G; Utomo AR; Tandean S; Loe ML
Pan Afr Med J; 2020; 36():309. PubMed ID: 33282092
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma.
Hareedy AA; Rohim EZA; Al Sheikh SAM; Al Shereef ZAEA
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4333-4338. PubMed ID: 36580017
[TBL] [Abstract][Full Text] [Related]
3. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
[TBL] [Abstract][Full Text] [Related]
4. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
6. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
9. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
10. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
11. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
[TBL] [Abstract][Full Text] [Related]
12. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
[TBL] [Abstract][Full Text] [Related]
13. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).
Leibetseder A; Ackerl M; Flechl B; Wöhrer A; Widhalm G; Dieckmann K; Kreinecker SS; Pichler J; Hainfellner J; Preusser M; Marosi C
Neuro Oncol; 2013 Jan; 15(1):112-21. PubMed ID: 23223340
[TBL] [Abstract][Full Text] [Related]
14. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
[TBL] [Abstract][Full Text] [Related]
15. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
16. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
17. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
18. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
19. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
20. [Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].
Kamoshima Y; Motegi H; Terasaka S; Kobayashi H; Yamaguchi S; Murata J; Tanaka S; Houkin K
No Shinkei Geka; 2012 Feb; 40(2):129-35. PubMed ID: 22281465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
